Not medical advice. This site is general information only. In an emergency call your local emergency number. For advice about your own health, speak to a doctor, pharmacist or other qualified health professional.
IPASS
About the Trial
The Iressa Pan Asia Study randomized 1,217 East Asian never or light smokers with lung adenocarcinoma to gefitinib or carboplatin paclitaxel. Gefitinib improved progression free survival overall, but the effect depended on mutation status: among the roughly 60 percent of tested tumors with EGFR mutations, gefitinib roughly halved the risk of progression, while in wild type tumors chemotherapy did better. This prespecified biomarker analysis proved targeted therapy requires the target. IPASS, with NEJ002 and EURTAC, established routine EGFR mutation testing in lung adenocarcinoma and started the molecular stratification of lung cancer that now includes ALK, ROS1, RET, MET, and more. Lung oncology became the paradigm of genomically driven treatment.
Related Trials
DCCT
The Diabetes Control and Complications Trial randomized 1,441 type 1 diabetes patients to intensive versus conventional insulin th...
UKPDS
The UK Prospective Diabetes Study followed over 5,000 newly diagnosed type 2 diabetes patients for a median of 10 years. Intensive...
ACCORD
The Action to Control Cardiovascular Risk in Diabetes trial tested intensive glucose control targeting HbA1c under 6.0 percent in ...
ADVANCE
ADVANCE randomized 11,140 type 2 diabetes patients to intensive gliclazide based glucose control or standard therapy. Intensive co...